Stock Events

Stock Events

Eiger BioPharmaceuticals 

$1.73
17
+$0+0% Monday 22:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

23AugExpected
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
-7.5
-5.11
-2.71
-0.32
Expected EPS
-3.3
Actual EPS
N/A

Financials

-717.71%Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
13.48MRevenue
-96.78MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EIGR. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences is a biopharmaceutical company that competes with Eiger in the development of treatments for viral diseases, including hepatitis delta virus (HDV).
Merck
MRK
Mkt Cap298.84B
Merck & Co., Inc. is a global healthcare company that develops antiviral drugs, competing with Eiger in areas such as infectious disease treatment.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie competes with Eiger in researching and developing treatments for various diseases, including viral infections, leveraging its biopharmaceutical capabilities.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals is involved in creating antiviral drugs among other treatments, presenting competition to Eiger in the infectious disease market.
GSK
GSK
Mkt Cap113.29B
GlaxoSmithKline is a large pharmaceutical company that competes with Eiger in the development of vaccines and treatments for viral diseases.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb is a global biopharmaceutical company that develops drugs for various diseases, including viral infections, competing with Eiger's focus areas.
Pfizer
PFE
Mkt Cap161.09B
Pfizer is a global pharmaceutical corporation that competes with Eiger in the development and commercialization of antiviral drugs.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its pharmaceutical division Janssen, competes with Eiger in the research and development of treatments for infectious diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals is known for its innovative treatments and competes with Eiger in the development of therapies for infectious diseases.
Novartis
NVS
Mkt Cap297.32B
Novartis is a global healthcare company that competes with Eiger in the development of new therapies for diseases, including viral infections.

About

Health Technology
Biotechnology
Manufacturing
Biological Product (except Diagnostic) Manufacturing
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Show more...
CEO
Krisztina Zsebo
Employees
56
Country
US
ISIN
US28249U1051
WKN
000A2AF9X

Listings

0 Comments

Share your thoughts

FAQ

What is Eiger BioPharmaceuticals stock price today?▼
The current price of EIGR is $1.73 USD — it has increased by +0% in the past 24 hours. Watch Eiger BioPharmaceuticals stock price performance more closely on the chart.
What is Eiger BioPharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Eiger BioPharmaceuticals stocks are traded under the ticker EIGR.
What is Eiger BioPharmaceuticals revenue for the last year?▼
Eiger BioPharmaceuticals revenue for the last year amounts to 13.48M USD.
What is Eiger BioPharmaceuticals net income for the last year?▼
EIGR net income for the last year is -96.78M USD.
How many employees does Eiger BioPharmaceuticals have?▼
As of April 07, 2026, the company has 56 employees.
In which sector is Eiger BioPharmaceuticals located?▼
Eiger BioPharmaceuticals operates in the Manufacturing sector.
When did Eiger BioPharmaceuticals complete a stock split?▼
The last stock split for Eiger BioPharmaceuticals was on January 08, 2024 with a ratio of 1:30.
Where is Eiger BioPharmaceuticals headquartered?▼
Eiger BioPharmaceuticals is headquartered in Palo Alto, US.